Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

Cytochrome P450 (CYP) enzymes are responsible for the biotransformation of drugs, xenobiotics, and endogenous substances. This enzymatic activity can be modulated by intrinsic and extrinsic factors, modifying the organism’s response to medications. Among the factors that are responsible for enzyme i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer chemotherapy and pharmacology Ročník 87; číslo 3; s. 295 - 309
Hlavní autoři: Stipp, Maria Carolina, Acco, Alexandra
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2021
Springer Nature B.V
Témata:
Biotransformation
Breast cancer
Cancer
Cancer Research
Carcinogenesis
Cell survival
Chemotherapy
Cytochrome
Cytochrome P450
Cytokines
Enzymatic activity
Enzymes
Hepatocellular carcinoma
Inflammation
Interleukin 1
Interleukin 6
Leukocytes (neutrophilic)
Liver cancer
Lung cancer
Lymphocytes
Macrophages
Medicine
Medicine & Public Health
Mutation
Oncology
Pharmacology/Toxicology
Review Article
Toxicity
Tumor microenvironment
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Xenobiotics
γ-Interferon
Chemotherapy
Hepatocarcinoma
Breast cancer
CYP450
Enzyme
Lung cancer
ISSN:0344-5704, 1432-0843, 1432-0843
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cytochrome P450 (CYP) enzymes are responsible for the biotransformation of drugs, xenobiotics, and endogenous substances. This enzymatic activity can be modulated by intrinsic and extrinsic factors, modifying the organism’s response to medications. Among the factors that are responsible for enzyme inhibition or induction is the release of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ), from macrophages, lymphocytes, and neutrophils. These cells are also present in the tumor microenvironment, participating in the development of cancer, a disease that is characterized by cellular mutations that favor cell survival and proliferation. Mutations also occur in CYP enzymes, resulting in enzymatic polymorphisms and modulation of their activity. Therefore, the inhibition or induction of CYP enzymes by proinflammatory cytokines in the tumor microenvironment can promote carcinogenesis and affect chemotherapy, resulting in adverse effects, toxicity, or therapeutic failure. This review discusses the relevance of CYPs in hepatocarcinoma, breast cancer, lung cancer, and chemotherapy by reviewing in vitro, in vivo, and clinical studies. We also discuss the importance of elucidating the relationships between inflammation, CYPs, and cancer to predict drug interactions and therapeutic efficacy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0344-5704
1432-0843
1432-0843
DOI:10.1007/s00280-020-04181-2